Aliceblue ANTInstall and trade smarter everywhere
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Indegene Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
Key metrics and details at a glance.
Price Band
₹452
Per ShareLot Size
33 Shares
Minimum Investment
₹14,916
Issue Size
₹1,841.76 Cr
Face Value
₹2
Per ShareIPO Type
Book Building
Retail Quota
35%
QIB Quota
50%
NII Quota
15%
Important dates for your applying strategy.
Business model, operations, and market positioning.
Issue Type
Book Building
ISIN
INE065X01017
Indegene Limited provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. The Company combines over two decades of healthcare domain expertise and its technology platforms to provide solutions that assist life science companies in clinical trials, support their regulatory and safety operations, aid in the launch of their products in the market and drive sales and marketing through the life cycle of their products. Its portfolio of solutions covers all aspects of commercial, medical, regulatory and R&D operations of life sciences companies. As of December 31, 2023, the company had 65 active clients whom it caters to from six operation hubs and 17 offices located across North America, Europe and Asia.
The life sciences industry primarily comprises biopharmaceutical companies and medical devices companies, whose combined sales were estimated at Rs.138.3 trillion (US$1.8 trillion) in 2023, with biopharmaceutical companies constituting 69% or Rs.95.4 trillion (US$ 1.2 trillion) of such sales. Combined sales of biopharmaceutical companies and medical devices companies are estimated to reach Rs.163.5 trillion (US$2.1 trillion) by 2026 driven by a rise in aging population, increasing prevalence of chronic diseases and discovery of new diseases, among other factors. Life sciences operations expenditure (which includes spends on marketing and sales, drug discovery and clinical trials, regulatory and medical affairs, manufacturing, supply chain and distribution and pharmacovigilance or complaints management) was estimated at Rs.12.0 trillion (US$156 billion) in 2022 and is expected to grow at a CAGR of 6.5% to reach Rs.15.5 trillion (US$201 billion) in 2026 in line with growth in industry sales.
Revenue, profit after tax and total assets across the last 3 reported financial years.
Amount in ₹ crore
How the company plans to utilize IPO proceeds.
The funds raised through this IPO will be used for:
Initial public offering of 40,766,550* equity shares of face value of Rs. 2 each ("Equity Shares") of Indegene Limited (The "Company" or the "Company") for cash at a price of Rs. 452 per equity share (including a premium of Rs. 450 per equity share) ("Offer Price") aggregating Rs. 1841.76 crores* (the "Offer") comprising a fresh issue of 16,833,818* equity shares aggregating to Rs. 760.00 crores (the "Fresh Issue") and an offer for sale of 23,932,732* equity shares aggregating to Rs. 1081.76 crores* (the "Offer for Sale"), consisting of 1,118,596* equity shares aggregating to Rs. 50.56 crores* by Manish Gupta, 3,233,818* equity shares aggregating to Rs. 146.17 crores* by Rajesh Bhaskaran Nair, 1,151,454* equity shares aggregating to Rs. 52.05 crores* by Anita Nair (collectively with Manish Gupta and Rajesh Bhaskaran Nair, the "Individual Selling Shareholders"), 3,600,000* equity shares aggregating to Rs. 162.72 crores* by Vida Trustees Private Limited, 2,657,687* equity shares aggregating to Rs. 120.13 crores* by BPC Genesis Fund I SPV, Ltd, 1,378,527* equity shares aggregating to Rs. 62.31 crores* by BPC Genesis Fund I-A SPV, Ltd. and 10,792,650* equity shares aggregating to Rs. 487.83* crores by CA Dawn Investments (collectively with Vida Trustees Private Limited, BPC Genesis Fund I SPV, Ltd and BPC Genesis Fund I-A SPV, Ltd., the "Investor Selling Shareholders" and collectively with the individual selling shareholders, the "Selling Shareholders" and such equity shares, the "Offered Shares"). The offer includes a reservation of 296,208* equity shares, aggregating to Rs. 12.50 crores (constituting 0.12%* of the post-offer paid-up equity share capital), for subscription by eligible employees ("Employee Reservation Portion"). The company, in consultation with the brlms offered a discount of Rs. 30 per equity share) to eligible employees who bid in the employee reservation portion ("Employee Discount"). The offer less the employee reservation portion is hereinafter referred to as the "Net Offer". The offer and the net offer constitute 17.04%* and 16.91%* of the post-offer paid-up equity share capital of the company. *Subject to finalisation of basis of allotment
*Subject to approvals and market conditions.
Key competitive advantages and factors to consider before investing.
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Indegene Limited was incorporated as `Indegene Lifesystems Private Limited' at Ahmedabad, Gujarat, as a private limited company, under the Companies Act, 1956, pursuant to a certificate of incorporation dated October 16, 1998, issued by the Registrar of Companies, Gujarat, Dadra & Nagar Haveli at Ahmedabad. Thereafter, the registered office of the Company was shifted from Gujarat to Karnataka in June 2003, and then, from Karnataka to Maharashtra in May 2014. Further, pursuant to a resolution passed by its Shareholders at the EGM held on February 29, 2016 the name of the Company was changed to `Indegene Private Limited' and a fresh certificate of incorporation was issued by the Registrar of Companies, Maharashtra at Mumbai on May 26, 2016. The name of the Company was changed to better reflect the nature of business undertaken by the Company. Thereafter, the registered office of the Company was shifted from Maharashtra to Karnataka in February 2017. Subsequently, the Company was converted from a private limited company to a public limited company, pursuant to a special resolution passed by its Shareholders at the EGM held on November 7, 2022 and the name of the Company was changed to `Indegene Limited' and a fresh certificate of incorporation was issued to the Company by the RoC, on November 17, 2022.
Indegene Limited had 65 active clients whom it caters to from six operation hubs and 17 offices located across North America, Europe and Asia.
Amount in ₹ crore
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY24 to FY26.